GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Fulgent Genetics Inc (FRA:7F0) » Definitions » Profitability Rank

Fulgent Genetics (FRA:7F0) Profitability Rank : 4 (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Fulgent Genetics Profitability Rank?

Fulgent Genetics has the Profitability Rank of 4.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Fulgent Genetics's Operating Margin % for the quarter that ended in Dec. 2023 was -43.81%. As of today, Fulgent Genetics's Piotroski F-Score is 4.


Competitive Comparison of Fulgent Genetics's Profitability Rank

For the Diagnostics & Research subindustry, Fulgent Genetics's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fulgent Genetics's Profitability Rank Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Fulgent Genetics's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Fulgent Genetics's Profitability Rank falls into.



Fulgent Genetics Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Fulgent Genetics has the Profitability Rank of 4.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Fulgent Genetics's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-28.323 / 64.653
=-43.81 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Fulgent Genetics has an F-score of 4 indicating the company's financial situation is typical for a stable company.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


Fulgent Genetics Profitability Rank Related Terms

Thank you for viewing the detailed overview of Fulgent Genetics's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Fulgent Genetics (FRA:7F0) Business Description

Traded in Other Exchanges
Address
4978 Santa Anita Avenue, Temple City, CA, USA, 91780
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. Genetic testing offers the possibility of early identification of a disease or a genetic predisposition to disease and enhanced disease treatment and prognosis. Fulgent's product portfolio includes Genes & Panels, Known Mutation, Genomic Testing, Hereditary Cancer, Carrier Screening, Tumor Profiling, and Sequencing Service. Its customers are categorized as Insurance; Institutional, which includes hospitals, medical institutions, laboratories, governmental bodies, municipalities, and large corporations; and Patients. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.

Fulgent Genetics (FRA:7F0) Headlines

No Headlines